Drugs to watch: Anticipated Q4 2023 launches
Pipeline includes therapies for Alzheimer’s disease, postpartum depression, obesity
The robust drug pipeline continues to flow as manufacturers seek approval from the U.S. Food & Drug Administration for new therapies. Anticipated launches in the fourth quarter of this year include an intravenous treatment for early symptomatic Alzheimer’s disease (donanemab, Eli Lilly). Also notable is the projected launch of Zurzuvae, an oral, rapid-acting, limited-duration treatment for postpartum depression (zuranalone, Biogen/Sage Therapeutics).
In the booming GLP-1 space, a new formulation of Eli Lilly’s Mounjaro (tirzepatide) is expected to be approved for the treatment of obesity in adults.
Discover additional insights
This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health.
©2023 CVS Health. All rights reserved.  091923